Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingNuclear Medical

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1963141

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1963141

Nuclear Medicine Market by Type, Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region - Global Forecast to 2030

PUBLISHED:
PAGES: 536 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global nuclear medicine market is projected to reach USD 21.01 billion by 2030, growing from USD 10.41 billion in 2025 at a CAGR of 15.1% during the forecast period. This projection is driven by the growing demand for diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes in the oncology, cardiology, and neurology fields.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsType, Application, Volume Assessment, End User, and Region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

Additionally, the increased utilization of targeted radionuclide therapies, growth in cyclotron and reactor-based production of radioisotopes, and enhanced availability of these products through nuclear pharmacy networks are enhancing the growth of the market. Moreover, there is a significant increase in the use of radiopharmaceuticals across the globe as new ones are constantly developed and approved by regulatory bodies. This increased use of radiopharmaceuticals is further driving the growth of the market.

Nuclear Medicine Market - IMG1

"The hospitals segment is projected to account for the largest share during the forecast period."

By end user, the hospitals segment is projected to account for the largest share of the nuclear medicine market during the forecast period. This projection is based on the capability of hospitals in preparing and administering radiopharmaceuticals through complex processes, available licensed facilities to deal with radioisotopes, and the presence of specialized nuclear medicine experts. Additionally, the presence of large volumes of patients, combined with diagnostic and therapeutic services, and well-established reimbursement systems in hospitals, is further expected to drive the growth of the segment in the coming years.

"The therapeutic applications segment is projected to register a higher growth than the diagnostic applications segment during the forecast period."

The therapeutic applications segment is projected to register a higher growth than the diagnostics applications segment during the forecast period. This projection is driven by the rising application of targeted radiopharmaceutical therapies and radioisotopes in treating cancer, especially in theranostics. Increasing clinical efficacy of radionuclide therapies and growing regulatory approval and investment in the production of therapeutic radioisotopes are boosting the acceptance across healthcare providers.

"Asia Pacific is projected to witness the highest growth rate during the forecast period."

Asia Pacific is projected to register the highest growth in the nuclear medicine market over the forecast period. This is due to the rising demand for radiopharmaceuticals and radioisotopes because of factors like increasing cancer prevalence, hospital facilities expansion, and growing access to nuclear medicine services. Additionally, the production of radioisotopes and the enhancement of regulatory infrastructure and supply chains by the governments are also increasing the growth of the markets in the region faster. Moreover, the growing healthcare spending and the rising awareness of early diagnosis and specific treatments are contributing to the rise in the number of nuclear medicine procedures.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The breakdown of primary participants is mentioned below:

  • By Company Type - Tier 1 - 64%; Tier 2 - 23%; and Tier 3 - 13%
  • By Designation - C Level - 35%; Director Level - 25%; and Others - 40%
  • By Region - North America - 44%; Europe - 23%; Asia Pacific - 28%; Latin America - 3%; Middle East & Africa - 2%

Key Players in the Nuclear Medicine Market

The key players operating in the nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institutes of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE Elit (Turkey).

Research Coverage

The report analyzes the nuclear medicine market and aims to estimate the market size and future growth potential of various market segments by type, application, volume assessment, end user, and region. The report provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.

This report provides insights into:

  • Analysis of key drivers (Increasing incidence and prevalence of target conditions, development of alpha-radioimmunotherapy-based targeted cancer treatments, initiatives to reduce demand and supply gap of Mo-99), restraints (Short half-life of radiopharmaceuticals), opportunities (Use of radiopharmaceuticals in neurological applications, growth opportunities in emerging economies), challenges (Hospital budget cuts and high equipment costs) influencing the growth of the nuclear medicine market
  • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product launches in the nuclear medicine market
  • Market Development: Comprehensive information on the lucrative emerging markets (based on type, application, volume assessment, and end user) across regions
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the nuclear medicine market
  • Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings, and capabilities of the leading players [GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), and Lantheus Holdings, Inc. (US)] operating in the nuclear medicine market
Show more
Product Code: PH 3590

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 INCLUSIONS & EXCLUSIONS
    • 1.3.4 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN NUCLEAR MEDICINE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 NUCLEAR MEDICINE MARKET OVERVIEW
  • 3.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE & COUNTRY
  • 3.3 NUCLEAR MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
  • 3.4 NUCLEAR MEDICINE MARKET: DEVELOPED VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing incidence and prevalence of target conditions
      • 4.2.1.2 Rapid expansion of radioligand & targeted radionuclide therapy
      • 4.2.1.3 Strategic entry of large pharma & capital inflows
      • 4.2.1.4 Initiatives to reduce demand and supply gap of Mo-99
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Short half-life of radiopharmaceuticals
      • 4.2.2.2 Structural isotope supply fragility
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Development of alpha-radioimmunotherapy-based targeted cancer treatments
      • 4.2.3.2 Use of radiopharmaceuticals in neurological applications
      • 4.2.3.3 Growth opportunities in emerging economies and expanding PET Infrastructure
    • 4.2.4 CHALLENGES
      • 4.2.4.1 High capital intensity of nuclear medicine infrastructure and hospital budget cuts
      • 4.2.4.2 Workforce shortage in nuclear medicine
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 THREAT OF NEW ENTRANTS
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    • 5.2.4 TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024
    • 5.5.2 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY REGION, 2024
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT SCENARIO FOR HS CODE 2844
    • 5.6.2 EXPORT SCENARIO FOR HS CODE 2844
    • 5.6.3 IMPORT SCENARIO FOR HS CODE 3002
    • 5.6.4 EXPORT SCENARIO FOR HS CODE 3002
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
  • 5.11 IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON COUNTRY/REGION
      • 5.11.4.1 US
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Hospitals
      • 5.11.5.2 Diagnostic & imaging centers
      • 5.11.5.3 Research & academic institutes

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 NEXT-GENERATION RADIOLIGAND THERAPY & THERANOSTICS
    • 6.1.2 RADIOISOTOPE PRODUCTION TECHNOLOGIES
    • 6.1.3 HIGH-SPECIFIC-ACTIVITY RADIOLABELING AND CHELATION CHEMISTRY
    • 6.1.4 GMP HOT-CELL MANUFACTURING & RADIOPHARMACEUTICAL QUALITY CONTROL
    • 6.1.5 COLD KIT & GENERATOR TECHNOLOGIES
    • 6.1.6 DECENTRALIZED ISOTOPE PRODUCTION & ADVANCED RADIOPHARMACY SYSTEMS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 AUTOMATED RADIOTRACER SYNTHESIS & DISPENSING SYSTEMS
    • 6.2.2 DOSIMETRY & TREATMENT PLANNING TECHNOLOGIES
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 TARGET DISCOVERY & RADIOLIGAND DESIGN PLATFORMS
    • 6.3.2 INTEGRATED THERANOSTIC WORKFLOWS & DATA PLATFORMS
    • 6.3.3 AI-ENABLED QUANTITATIVE IMAGING & WORKFLOW AUTOMATION
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE MARKET
    • 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
    • 6.6.1 PRECISION ONCOLOGY & THERANOSTICS EXPANSION
    • 6.6.2 PERSONALIZED RADIONUCLIDE THERAPY USING DOSIMETRY-GUIDED DOSING
    • 6.6.3 EARLY DISEASE DETECTION & RISK STRATIFICATION
    • 6.6.4 NEURODEGENERATIVE & NEUROINFLAMMATORY DISORDERS
    • 6.6.5 INFLAMMATION, INFECTION, AND IMMUNE SYSTEM IMAGING
  • 6.7 IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN NUCLEAR MEDICINE MARKET
    • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
      • 6.7.3.1 Clinical validation of AI-enabled standardization and workflow efficiency in PSMA PET imaging for prostate cancer
    • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
      • 6.7.4.1 Radiopharmacy, manufacturing, and quality operations
      • 6.7.4.2 Clinical imaging, dosimetry, and treatment planning infrastructure
      • 6.7.4.3 Hospital systems, regulatory compliance, and theranostic data platforms
    • 6.7.5 USER READINESS AND IMPACT ASSESSMENT
      • 6.7.5.1 User readiness
        • 6.7.5.1.1 User A: Hospitals
        • 6.7.5.1.2 User B: Diagnostic & imaging centers
      • 6.7.5.2 Impact assessment
        • 6.7.5.2.1 User A: Hospitals
          • 6.7.5.2.1.1 Implementation
          • 6.7.5.2.1.2 Impact
        • 6.7.5.2.2 User B: Diagnostic & imaging centers
          • 6.7.5.2.2.1 Implementation
          • 6.7.5.2.2.2 Impact

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Latin America
      • 7.1.2.5 Middle East & Africa
    • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 INTRODUCTION
  • 8.2 DECISION-MAKING PROCESS
  • 8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.3.2 BUYING CRITERIA
  • 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
    • 8.5.1 UNMET NEEDS
    • 8.5.2 END-USER EXPECTATIONS
  • 8.6 MARKET PROFITABILITY

9 NUCLEAR MEDICINE MARKET, BY TYPE

  • 9.1 INTRODUCTION
  • 9.2 DIAGNOSTIC NUCLEAR MEDICINE
    • 9.2.1 SPECT RADIOPHARMACEUTICALS
      • 9.2.1.1 Tc-99m
        • 9.2.1.1.1 Dominant role of Tc-99m in SPECT to boost market growth
      • 9.2.1.2 I-123
        • 9.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive demand
      • 9.2.1.3 Tl-201
        • 9.2.1.3.1 Most commonly used substitute for Tc-99m in cardiac stress tests to support market growth
      • 9.2.1.4 Ga-67
        • 9.2.1.4.1 Long half-life of Ga-67 to facilitate easy sales and distribution
      • 9.2.1.5 Other SPECT radiopharmaceuticals
    • 9.2.2 PET RADIOPHARMACEUTICALS
      • 9.2.2.1 F-18
        • 9.2.2.1.1 Advantages such as highly accurate, metabolism-based cancer imaging to boost demand
      • 9.2.2.2 Rb-82
        • 9.2.2.2.1 High accuracy offered by Rb-82 isotopes to support market growth
      • 9.2.2.3 Other PET radiopharmaceuticals
  • 9.3 THERAPEUTIC NUCLEAR MEDICINE
    • 9.3.1 ALPHA EMITTERS
      • 9.3.1.1 Ra-223
        • 9.3.1.1.1 Rising metastatic prostate cancer burden and demand for bone-targeted, outpatient alpha therapy to drive adoption
    • 9.3.2 BETA EMITTERS
      • 9.3.2.1 I-131
        • 9.3.2.1.1 I-131 to account for largest share of beta emitters market during forecast period
      • 9.3.2.2 Y-90
        • 9.3.2.2.1 Rising incidence of liver cancers and hepatocellular carcinoma to propel growth
      • 9.3.2.3 Sm-153
        • 9.3.2.3.1 Increasing incidence of bone metastasis to drive market
      • 9.3.2.4 Lu-177
        • 9.3.2.4.1 Rising cancer burden and expanding PRRT adoption to fuel growth
      • 9.3.2.5 Other beta emitters
    • 9.3.3 BRACHYTHERAPY ISOTOPES
      • 9.3.3.1 I-125
        • 9.3.3.1.1 I-125 to account for largest share of brachytherapy isotopes market
      • 9.3.3.2 Ir-192
        • 9.3.3.2.1 Precise, high-dose brachytherapy across multiple cancers to propel market
      • 9.3.3.3 Pd-103
        • 9.3.3.3.1 Ability to make brachytherapy permanent implant seeds for early-stage prostate cancer to drive adoption
      • 9.3.3.4 Cs-131
        • 9.3.3.4.1 Growing use of Cs-131 in gynecological applications to aid growth
      • 9.3.3.5 Other brachytherapy isotopes

10 NUCLEAR MEDICINE MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 DIAGNOSTIC APPLICATIONS
    • 10.2.1 SPECT APPLICATIONS
      • 10.2.1.1 Cardiology
        • 10.2.1.1.1 Rising global cardiovascular disease burden and expanding, evidence-backed cardiology applications to drive growth
      • 10.2.1.2 Bone scans
        • 10.2.1.2.1 High precision of SPECT to boost adoption of bone scans
      • 10.2.1.3 Thyroid
        • 10.2.1.3.1 Rising demand for combination SPECT/CT therapy to drive market growth
      • 10.2.1.4 Pulmonary scans
        • 10.2.1.4.1 High accuracy and sensitivity of SPECT/CT pulmonary imaging to boost market
      • 10.2.1.5 Other SPECT applications
    • 10.2.2 PET APPLICATIONS
      • 10.2.2.1 Oncology
        • 10.2.2.1.1 Increasing incidence of cancer to fuel market growth
      • 10.2.2.2 Cardiology
        • 10.2.2.2.1 Growing preference for FDG in cardiac imaging to propel market
      • 10.2.2.3 Neurology
        • 10.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson's disease to increase adoption of PET imaging
      • 10.2.2.4 Other PET applications
  • 10.3 THERAPEUTIC APPLICATIONS
    • 10.3.1 THYROID INDICATIONS
      • 10.3.1.1 Increasing prevalence of thyroid disorders to boost market
    • 10.3.2 BONE METASTASIS
      • 10.3.2.1 Introduction of novel therapies for bone metastasis to positively impact market growth
    • 10.3.3 ENDOCRINE TUMORS
      • 10.3.3.1 US to dominate therapeutic nuclear medicine market for endocrine tumor applications
    • 10.3.4 LYMPHOMA
      • 10.3.4.1 Development of new isotopes for treatment of lymphoma to present huge growth opportunities
    • 10.3.5 OTHER THERAPEUTIC APPLICATIONS

11 NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT

  • 11.1 INTRODUCTION
  • 11.2 DIAGNOSTIC PROCEDURES
    • 11.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH
  • 11.3 THERAPEUTIC PROCEDURES
    • 11.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH

12 NUCLEAR MEDICINE MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 HOSPITALS
    • 12.2.1 GROWING VOLUME OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET GROWTH
  • 12.3 DIAGNOSTIC & IMAGING CENTERS
    • 12.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
  • 12.4 ACADEMIC & RESEARCH INSTITUTES
    • 12.4.1 INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH
  • 12.5 OTHER END USERS

13 NUCLEAR MEDICINE MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 13.2.2 US
      • 13.2.2.1 US to dominate North American nuclear medicine market during forecast period
    • 13.2.3 CANADA
      • 13.2.3.1 Increasing initiatives for medical isotope development to support market growth
  • 13.3 EUROPE
    • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 13.3.2 GERMANY
      • 13.3.2.1 Well-established healthcare system to drive market growth
    • 13.3.3 FRANCE
      • 13.3.3.1 Rising incidence of diseases such as cancer, Alzheimer's, and Parkinson's disease to favor market growth
    • 13.3.4 UK
      • 13.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth
    • 13.3.5 ITALY
      • 13.3.5.1 Aging demographics, high procedure volumes, increasing cancer incidence, and domestic isotope self-sufficiency to fuel growth
    • 13.3.6 SPAIN
      • 13.3.6.1 Rising disease prevalence, regulatory modernization, and targeted radioligand expansion to create supportive environment
    • 13.3.7 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 13.4.2 JAPAN
      • 13.4.2.1 Japan to dominate APAC nuclear medicine market
    • 13.4.3 CHINA
      • 13.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market
    • 13.4.4 INDIA
      • 13.4.4.1 Rising cancer and cardiovascular disease burden and rapid expansion of nuclear medicine infrastructure to boost market
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Accelerating PET utilization and maturing domestic RPT innovation ecosystem to augment market
    • 13.4.6 AUSTRALIA
      • 13.4.6.1 Rising cancer prevalence, high PET penetration, and growing domestic isotope production to support growth
    • 13.4.7 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 13.5.2 BRAZIL
      • 13.5.2.1 Rising cancer incidence and expanding imaging infrastructure to drive market
    • 13.5.3 MEXICO
      • 13.5.3.1 Rising cancer and cardiovascular disease burden and expanding private-sector PET access to drive market
    • 13.5.4 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 13.6.2 GCC COUNTRIES
      • 13.6.2.1 Growing healthcare needs and favorable government support to boost market
    • 13.6.3 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET
  • 14.3 REVENUE ANALYSIS, 2020-2024
  • 14.4 MARKET SHARE ANALYSIS, 2024
  • 14.5 BRAND/PRODUCT COMPARISON
  • 14.6 COMPANY VALUATION & FINANCIAL METRICS
    • 14.6.1 FINANCIAL METRICS
    • 14.6.2 COMPANY VALUATION
  • 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 14.7.1 STARS
    • 14.7.2 EMERGING LEADERS
    • 14.7.3 PERVASIVE PLAYERS
    • 14.7.4 PARTICIPANTS
    • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 14.7.5.1 Company footprint
      • 14.7.5.2 Region footprint
      • 14.7.5.3 Type footprint
      • 14.7.5.4 Application footprint
  • 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.8.1 PROGRESSIVE COMPANIES
    • 14.8.2 RESPONSIVE COMPANIES
    • 14.8.3 DYNAMIC COMPANIES
    • 14.8.4 STARTING BLOCKS
    • 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 14.8.5.1 Detailed list of key startups/SMEs
      • 14.8.5.2 Competitive benchmarking of startups/SMEs
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT APPROVALS
    • 14.9.2 DEALS
    • 14.9.3 EXPANSIONS
    • 14.9.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 NOVARTIS AG
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Product approvals
        • 15.1.1.3.2 Deals
        • 15.1.1.3.3 Expansions
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Right to win
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses & competitive threats
    • 15.1.2 LANTHEUS HOLDINGS, INC.
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Deals
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Right to win
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses & competitive threats
    • 15.1.3 GE HEALTHCARE
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Product approvals
        • 15.1.3.3.2 Deals
        • 15.1.3.3.3 Expansions
        • 15.1.3.3.4 Other developments
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Right to win
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses & competitive threats
    • 15.1.4 CURIUM
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Product approvals & enhancements
        • 15.1.4.3.2 Deals
        • 15.1.4.3.3 Expansions
        • 15.1.4.3.4 Other developments
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Right to win
        • 15.1.4.4.2 Strategic choices
        • 15.1.4.4.3 Weaknesses & competitive threats
    • 15.1.5 TELIX PHARMACEUTICALS LIMITED
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Product approvals
        • 15.1.5.3.2 Deals
        • 15.1.5.3.3 Other developments
      • 15.1.5.4 MnM view
        • 15.1.5.4.1 Right to win
        • 15.1.5.4.2 Strategic choices
        • 15.1.5.4.3 Weaknesses & competitive threats
    • 15.1.6 SIEMENS HEALTHINEERS
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Deals
        • 15.1.6.3.2 Other developments
    • 15.1.7 CHINA ISOTOPE & RADIATION CORPORATION
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Other developments
    • 15.1.8 BAYER AG
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Deals
    • 15.1.9 BRACCO IMAGING S.P.A.
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products offered
      • 15.1.9.3 Recent developments
        • 15.1.9.3.1 Product approvals
        • 15.1.9.3.2 Deals
        • 15.1.9.3.3 Other developments
    • 15.1.10 CARDINAL HEALTH
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products offered
      • 15.1.10.3 Recent developments
        • 15.1.10.3.1 Deals
    • 15.1.11 JUBILANT PHARMOVA LIMITED
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
      • 15.1.11.3 Recent developments
        • 15.1.11.3.1 Product approvals
        • 15.1.11.3.2 Deals
        • 15.1.11.3.3 Other developments
    • 15.1.12 ELI LILLY AND COMPANY
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
      • 15.1.12.3 Recent developments
        • 15.1.12.3.1 Deals
        • 15.1.12.3.2 Other developments
    • 15.1.13 BWXT MEDICAL LTD.
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products offered
      • 15.1.13.3 Recent developments
        • 15.1.13.3.1 Product approvals
    • 15.1.14 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products offered
      • 15.1.14.3 Recent developments
        • 15.1.14.3.1 Deals
    • 15.1.15 ECKERT & ZIEGLER
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products offered
      • 15.1.15.3 Recent developments
        • 15.1.15.3.1 Product approvals
        • 15.1.15.3.2 Deals
        • 15.1.15.3.3 Expansions
    • 15.1.16 ISOTOPE JSC
      • 15.1.16.1 Business overview
      • 15.1.16.2 Products offered
      • 15.1.16.3 Recent developments
        • 15.1.16.3.1 Deals
        • 15.1.16.3.2 Other developments
    • 15.1.17 PDRADIOPHARMA INC.
      • 15.1.17.1 Business overview
      • 15.1.17.2 Products offered
      • 15.1.17.3 Recent developments
        • 15.1.17.3.1 Product launches & approvals
        • 15.1.17.3.2 Deals
        • 15.1.17.3.3 Expansions
    • 15.1.18 ITM ISOTOPE TECHNOLOGIES MUNICH SE
      • 15.1.18.1 Business overview
      • 15.1.18.2 Products offered
      • 15.1.18.3 Recent developments
        • 15.1.18.3.1 Product approvals
        • 15.1.18.3.2 Deals
        • 15.1.18.3.3 Expansions
        • 15.1.18.3.4 Other developments
    • 15.1.19 NARODOWE CENTRUM BADAN JĄDROWYCH OSRODEK RADIOIZOTOPOW - POLATOM
      • 15.1.19.1 Business overview
      • 15.1.19.2 Products offered
      • 15.1.19.3 Recent developments
        • 15.1.19.3.1 Deals
    • 15.1.20 ANSTO
      • 15.1.20.1 Business overview
      • 15.1.20.2 Products offered
      • 15.1.20.3 Recent developments
        • 15.1.20.3.1 Deals
        • 15.1.20.3.2 Other developments
  • 15.2 OTHER PLAYERS
    • 15.2.1 SHINE TECHNOLOGIES, LLC
    • 15.2.2 ISOTOPIA MOLECULAR IMAGING LTD.
    • 15.2.3 INSTITUTE OF ISOTOPES
    • 15.2.4 GLOBAL MEDICAL SOLUTIONS
    • 15.2.5 ISOTEX DIAGNOSTICS

16 RESEARCH METHODOLOGY

  • 16.1 RESEARCH DATA
  • 16.2 RESEARCH APPROACH
    • 16.2.1 SECONDARY RESEARCH
      • 16.2.1.1 Key data from secondary sources
    • 16.2.2 PRIMARY RESEARCH
      • 16.2.2.1 Primary sources
      • 16.2.2.2 Key data from primary sources
      • 16.2.2.3 Breakdown of primaries
      • 16.2.2.4 Insights from primary experts
  • 16.3 RESEARCH METHODOLOGY DESIGN
  • 16.4 MARKET SIZE ESTIMATION
    • 16.4.1 APPROACH 1: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH - SUPPLY-SIDE ANALYSIS)
    • 16.4.2 APPROACH 2: SECONDARY DATA & PRIMARY INTERVIEWS
    • 16.4.3 APPROACH 3: SEGMENTAL MARKET SIZE ASSESSMENT
    • 16.4.4 APPROACH 4: TOP-DOWN APPROACH
    • 16.4.5 GROWTH FORECAST
    • 16.4.6 GEOGRAPHIC MARKET ASSESSMENT (BY REGION AND COUNTRY)
  • 16.5 MARKET BREAKDOWN & DATA TRIANGULATION
  • 16.6 STUDY ASSUMPTIONS
  • 16.7 RESEARCH LIMITATIONS
    • 16.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 16.7.2 SCOPE-RELATED LIMITATIONS
  • 16.8 RISK ASSESSMENT

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS
Show more
Product Code: PH 3590

List of Tables

  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 MAIN MO-99 PRODUCTION REACTORS
  • TABLE 3 RADIOPHARMACEUTICALS: PHYSICAL HALF-LIFE AND MAJOR CLINICAL APPLICATIONS
  • TABLE 4 UK: NUCLEAR MEDICINE-RELATED WORKFORCE AND VACANCY DATA, 2021
  • TABLE 5 NUCLEAR MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 NUCLEAR MEDICINE MARKET: ROLE IN ECOSYSTEM
  • TABLE 7 INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024
  • TABLE 8 INDICATIVE PRICE OF NUCLEAR MEDICINE IN EASTERN EUROPE, BY TYPE, 2024
  • TABLE 9 INDICATIVE PRICE OF NUCLEAR MEDICINE IN MENAT REGION, BY TYPE, 2024
  • TABLE 10 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN INDIA, BY TYPE, 2024
  • TABLE 11 IMPORT VALUE FOR HS CODE 2844, 2020-2024 (USD THOUSAND)
  • TABLE 12 EXPORT VALUE FOR HS CODE 2844, 2020-2024 (USD THOUSAND)
  • TABLE 13 IMPORT VALUE FOR HS CODE 3002, 2020-2024 (USD THOUSAND)
  • TABLE 14 EXPORT VALUE FOR HS CODE 3002, 2020-2024 (USD THOUSAND)
  • TABLE 15 NUCLEAR MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 16 CASE 1: BETA-AMYLOID PET/CT IMAGING ENABLES ALZHEIMER'S PATIENT QUALIFICATION FOR ANTI-AMYLOID THERAPY AT NEW YORK-PRESBYTERIAN HOSPITAL
  • TABLE 17 CASE 2: WHOLE-BODY PET/CT WITH EXTENDED AXIAL FOV ENABLES DETECTION OF RARE PERICARDIAL RECURRENCE IN PLEURAL MESOTHELIOMA AT RIGSHOSPITALET
  • TABLE 18 CASE 3: CLINICAL AND OPERATIONAL IMPACT OF IMPLEMENTING AN INTEGRATED THERANOSTICS PROGRAM IN BRAZIL
  • TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE MARKET
  • TABLE 21 NUCLEAR MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 REGULATORY SCENARIO OF NORTH AMERICA
  • TABLE 28 REGULATORY SCENARIO OF EUROPE
  • TABLE 29 REGULATORY SCENARIO OF ASIA PACIFIC
  • TABLE 30 REGULATORY SCENARIO OF LATIN AMERICA
  • TABLE 31 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
  • TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 34 UNMET NEEDS IN NUCLEAR MEDICINE MARKET
  • TABLE 35 END-USER EXPECTATIONS IN NUCLEAR MEDICINE MARKET
  • TABLE 36 NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 37 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 38 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES
  • TABLE 40 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 41 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 TC-99M MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 43 I-123 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 TI-201 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 45 GA-67 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 OTHER SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 48 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 49 F-18 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 RB-82 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 OTHER PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 52 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 53 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 54 ALPHA EMITTERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 55 RA-223 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 BETA EMITTERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 57 BETA EMITTERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 I-131 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 59 Y-90 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 60 SM-153 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 61 LU-177 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 62 OTHER BETA EMITTERS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 64 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 I-125 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 66 IR-192 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 PD-103 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 68 CS-131 MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 69 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 71 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 72 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 73 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 74 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 75 NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 80 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 81 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 83 NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 85 NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 87 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 88 NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 90 NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 91 NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 92 NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2023-2030 (THOUSAND PROCEDURES)
  • TABLE 94 NUCLEAR MEDICINE MARKET, BY REGION, 2023-2030 (THOUSAND PROCEDURES)
  • TABLE 95 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2023-2030 (THOUSAND PROCEDURES)
  • TABLE 96 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2023-2030 (THOUSAND PROCEDURES)
  • TABLE 97 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2023-2030 (THOUSAND PROCEDURES)
  • TABLE 98 NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 99 NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 100 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 102 NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 103 NUCLEAR MEDICINE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 104 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 105 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 107 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 109 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 110 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 112 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 113 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 114 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 117 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 119 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 120 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 121 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 122 US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 123 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 124 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 125 US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 126 US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 127 US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 128 US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 129 US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 130 US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 131 US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 132 US: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 133 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 134 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 135 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 137 CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 138 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 139 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 140 CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 141 CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 142 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 143 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 144 CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 145 CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 146 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 147 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 148 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 150 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 151 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 152 EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 153 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 154 EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 155 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 156 EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 157 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 158 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 159 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 160 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 161 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 162 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 163 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 164 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 165 GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 167 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 168 GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 169 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 170 GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 172 GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 173 GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 174 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 175 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 176 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 177 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 178 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 179 FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 180 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 183 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 184 FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 185 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 186 FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 189 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 190 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 191 UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 192 UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 195 UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 196 UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 197 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 199 UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 200 UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 201 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 202 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 203 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 205 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 207 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 210 ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 211 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 212 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 213 ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 215 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 216 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 217 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 219 SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 220 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 221 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 223 SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 224 SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 225 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 226 SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 229 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 230 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 231 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 232 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 233 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 235 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 236 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 237 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 238 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 239 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 241 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 243 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 245 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 247 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 251 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 252 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 253 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 254 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 255 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 257 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 258 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 259 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 260 JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 261 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 262 JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 263 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 264 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 265 JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 266 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 267 JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 269 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 270 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 271 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 272 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 273 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 274 CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 275 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 276 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 277 CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 278 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 279 CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 280 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 282 CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 283 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 284 INDIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 285 INDIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 286 INDIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 287 INDIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 INDIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 289 INDIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 INDIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 291 INDIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 292 INDIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 293 INDIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 294 INDIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 INDIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 296 INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 297 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 298 SOUTH KOREA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 299 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 301 SOUTH KOREA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 303 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 304 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 305 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 306 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 307 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 308 SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 309 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 310 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 311 AUSTRALIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 312 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 313 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 314 AUSTRALIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 315 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 316 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 317 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 318 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 321 AUSTRALIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 322 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 323 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 324 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 325 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 326 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 328 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 329 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 331 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 332 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 334 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 335 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 336 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 337 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 338 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 339 LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 340 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 341 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 342 LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 343 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 344 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 345 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 346 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 347 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 348 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 349 LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 350 LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 351 BRAZIL: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 352 BRAZIL: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 354 BRAZIL: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 355 BRAZIL: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 356 BRAZIL: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 357 BRAZIL: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 BRAZIL: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 359 BRAZIL: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 360 BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 361 BRAZIL: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 362 BRAZIL: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 363 BRAZIL: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 364 MEXICO: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 365 MEXICO: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 366 MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 367 MEXICO: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 368 MEXICO: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 369 MEXICO: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 370 MEXICO: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 371 MEXICO: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 372 MEXICO: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 373 MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 374 MEXICO: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 375 MEXICO: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 376 MEXICO: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 377 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 378 REST OF LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 379 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 380 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 381 REST OF LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 383 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 384 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 385 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 386 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 390 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 391 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 392 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 393 MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 396 MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 397 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 398 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 399 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 400 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 401 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 402 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 403 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 404 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 405 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 406 GCC COUNTRIES: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 407 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 408 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 409 GCC COUNTRIES: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 410 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 411 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 412 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 413 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 414 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 415 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 416 GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 417 GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 418 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 419 REST OF MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 420 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 421 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 422 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 424 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 425 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 426 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 427 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 428 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 429 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 430 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 431 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE, JANUARY 2022-DECEMBER 2025
  • TABLE 432 NUCLEAR MEDICINE MARKET: DEGREE OF COMPETITION
  • TABLE 433 NUCLEAR MEDICINE MARKET: REGION FOOTPRINT
  • TABLE 434 NUCLEAR MEDICINE MARKET: TYPE FOOTPRINT
  • TABLE 435 NUCLEAR MEDICINE MARKET: APPLICATION FOOTPRINT
  • TABLE 436 NUCLEAR MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 437 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
  • TABLE 438 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY TYPE
  • TABLE 439 NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY APPLICATION
  • TABLE 440 NUCLEAR MEDICINE MARKET: PRODUCT APPROVALS, JANUARY 2022- DECEMBER 2025
  • TABLE 441 NUCLEAR MEDICINE MARKET: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 442 NUCLEAR MEDICINE MARKET: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 443 NUCLEAR MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 444 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 445 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 446 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 447 NOVARTIS AG: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 448 NOVARTIS AG: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 449 LANTHEUS HOLDINGS, INC.: COMPANY OVERVIEW
  • TABLE 450 LANTHEUS HOLDINGS, INC.: PRODUCTS OFFERED
  • TABLE 451 LANTHEUS HOLDINGS, INC.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 452 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 453 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 454 GE HEALTHCARE: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 455 GE HEALTHCARE: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 456 GE HEALTHCARE: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 457 GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 458 CURIUM: COMPANY OVERVIEW
  • TABLE 459 CURIUM: PRODUCTS OFFERED
  • TABLE 460 CURIUM: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 461 CURIUM: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 462 CURIUM: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 463 CURIUM: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 464 TELIX PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
  • TABLE 465 TELIX PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
  • TABLE 466 TELIX PHARMACEUTICALS LIMITED: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 467 TELIX PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 468 TELIX PHARMACEUTICALS LIMITED: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 469 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
  • TABLE 470 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
  • TABLE 471 SIEMENS HEALTHINEERS: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 472 SIEMENS HEALTHINEERS: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 473 CHINA ISOTOPE & RADIATION CORPORATION: COMPANY OVERVIEW
  • TABLE 474 CHINA ISOTOPE & RADIATION CORPORATION: PRODUCTS OFFERED
  • TABLE 475 CHINA ISOTOPE & RADIATION CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 476 BAYER AG: COMPANY OVERVIEW
  • TABLE 477 BAYER AG: PRODUCTS OFFERED
  • TABLE 478 BAYER AG: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 479 BRACCO IMAGING S.P.A.: COMPANY OVERVIEW
  • TABLE 480 BRACCO IMAGING S.P.A.: PRODUCTS OFFERED
  • TABLE 481 BRACCO IMAGING S.P.A.: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 482 BRACCO IMAGING S.P.A.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 483 BRACCO IMAGING S.P.A.: OTHER DEVELEOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 484 CARDINAL HEALTH: COMPANY OVERVIEW
  • TABLE 485 CARDINAL HEALTH: PRODUCTS OFFERED
  • TABLE 486 CARDINAL HEALTH: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 487 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW
  • TABLE 488 JUBILANT PHARMOVA LIMITED: PRODUCTS OFFERED
  • TABLE 489 JUBILANT PHARMOVA LIMITED: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 490 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 491 JUBILANT PHARMOVA LIMITED: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 492 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 493 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 494 ELI LILLY AND COMPANY: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 495 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 496 BWXT MEDICAL LTD.: COMPANY OVERVIEW
  • TABLE 497 BWXT MEDICAL LTD.: PRODUCTS OFFERED
  • TABLE 498 BWXT MEDICAL LTD.: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 499 NTP RADIOISOTOPES SOC LTD.: COMPANY OVERVIEW
  • TABLE 500 NTP RADIOISOTOPES SOC LTD.: PRODUCTS OFFERED
  • TABLE 501 NTP RADIOISOTOPES SOC LTD.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 502 ECKERT & ZIEGLER: COMPANY OVERVIEW
  • TABLE 503 ECKERT & ZIEGLER: PRODUCTS OFFERED
  • TABLE 504 ECKERT & ZIEGLER: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 505 ECKERT & ZIEGLER: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 506 ECKERT & ZIEGLER: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 507 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): COMPANY OVERVIEW
  • TABLE 508 ISOTOPE JSC: PRODUCTS OFFERED
  • TABLE 509 ISOTOPE JSC: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 510 ISOTOPE JSC: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 511 PDRADIOPHARMA INC.: COMPANY OVERVIEW
  • TABLE 512 PDRADIOPHARMA INC.: PRODUCTS OFFERED
  • TABLE 513 PDRADIOPHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 514 PDRADIOPHARMA INC.: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 515 PDRADIOPHARMA INC.: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 516 ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY OVERVIEW
  • TABLE 517 ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCTS OFFERED
  • TABLE 518 ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT APPROVALS, JANUARY 2022-DECEMBER 2025
  • TABLE 519 ITM ISOTOPE TECHNOLOGIES MUNICH SE: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 520 ITM ISOTOPE TECHNOLOGIES MUNICH SE: EXPANSIONS, JANUARY 2022-DECEMBER 2025
  • TABLE 521 ITM ISOTOPE TECHNOLOGIES MUNICH SE: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 522 NARODOWE CENTRUM BADAN JĄDROWYCH OSRODEK RADIOIZOTOPOW - POLATOM: COMPANY OVERVIEW
  • TABLE 523 NARODOWE CENTRUM BADAN JĄDROWYCH OSRODEK RADIOIZOTOPOW - POLATOM: PRODUCTS OFFERED
  • TABLE 524 NARODOWE CENTRUM BADAN JĄDROWYCH OSRODEK RADIOIZOTOPOW - POLATOM: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 525 ANSTO: COMPANY OVERVIEW
  • TABLE 526 ANSTO: PRODUCTS OFFERED
  • TABLE 527 ANSTO: DEALS, JANUARY 2022-DECEMBER 2025
  • TABLE 528 ANSTO: OTHER DEVELOPMENTS, JANUARY 2022-DECEMBER 2025
  • TABLE 529 RISK ASSESSMENT: NUCLEAR MEDICINE MARKET

List of Figures

  • FIGURE 1 NUCLEAR MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL NUCLEAR MEDICINE MARKET, 2023-2030
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2022-2025
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF NUCLEAR MEDICINE MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN NUCLEAR MEDICINE MARKET, 2025-2030
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NUCLEAR MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 8 RAPID EXPANSION OF RADIOLIGAND AND TARGETED RADIONUCLIDE THERAPY TO DRIVE MARKET GROWTH
  • FIGURE 9 DIAGNOSTIC NUCLEAR MEDICINE MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024
  • FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 11 GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD
  • FIGURE 12 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN EMERGING ECONOMIES, 2022-2050
  • FIGURE 14 NUCLEAR MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 GLOBAL GDP GROWTH, 2020-2030
  • FIGURE 16 NUCLEAR MEDICINE MARKET: VALUE CHAIN ANALYSIS (2024)
  • FIGURE 17 NUCLEAR MEDICINE MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 20 PATENT APPLICATION TRENDS IN NUCLEAR MEDICINE MARKET, 2015-2026
  • FIGURE 21 JURISDICTION & TOP APPLICANT ANALYSIS FOR NUCLEAR MEDICINE MARKET
  • FIGURE 22 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE MARKET (JANUARY 2015-FEBRUARY 2026)
  • FIGURE 23 MARKET POTENTIAL OF AI/GEN AI ON NUCLEAR MEDICINE ACROSS END USERS
  • FIGURE 24 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 27 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2024)
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2020-2024
  • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2024
  • FIGURE 31 NUCLEAR MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 32 EV/EBITDA OF KEY VENDORS
  • FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 34 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 35 NUCLEAR MEDICINE MARKET: COMPANY FOOTPRINT
  • FIGURE 36 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 38 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 39 GE HEALTHCARE: COMPANY SNAPSHOT (2024)
  • FIGURE 40 TELIX PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 41 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2024)
  • FIGURE 42 CHINA ISOTOPE & RADIATION CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 44 CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
  • FIGURE 45 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2024)
  • FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
  • FIGURE 47 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2024)
  • FIGURE 48 ANSTO: COMPANY SNAPSHOT (2024)
  • FIGURE 49 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
  • FIGURE 50 RESEARCH DESIGN
  • FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 52 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 53 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 54 NUCLEAR MEDICINE MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
  • FIGURE 55 NUCLEAR MEDICINE MARKET: REVENUE ANALYSIS OF TOP FOUR COMPANIES (2024)
  • FIGURE 56 NUCLEAR MEDICINE MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 57 NUCLEAR MEDICINE MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN NUCLEAR MEDICINE INDUSTRY
  • FIGURE 59 CAGR PROJECTIONS: NUCLEAR MEDICINE MARKET, 2025-2030
  • FIGURE 60 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!